Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Indevus’ Sanctura shows added bladder benefit
The researchers found that, when taken orally, trospium chloride not only helps control symptoms of overactive bladder systemically, but may also help control symptoms in the bladder itself
The researchers found that, when taken orally, trospium chloride not only helps control symptoms of overactive bladder systemically, but may also help control symptoms in the bladder itself
If he is correct, the researcher, Bertram Jacobs, may be able to create not only a vaccine that can cure smallpox infections in their early stages, but a
In the trial, the investigational compound decreased hemoglobin A1C levels (a measure of average blood glucose over a two- to three-month time period) at 24 weeks versus placebo.
The company expects to use the proceeds of the financing to fund its toll-like receptor 9 (TLR9) drug development activities, including an ongoing phase II trial of IMOxine
A supplemental new drug application (sNDA) for Risperdal (risperidone) was submitted to the FDA by Johnson & Johnson Pharmaceutical R&D (J&JPRD), a member of the Johnson & Johnson
The restructuring will enable Praecis to focus its resources on its most promising assets and programs and significantly reduce its cost structure. Going forward, the company will focus
Proquin XR (ciprofloxacin hydrochloride) is the first version of ciprofloxacin with nausea and diarrhea listed as “uncommon” adverse events in its label, rather than “common” adverse events. As
It is hoped the angiotensin receptor blocking (ARB) drug will help reduce cardiovascular death and reduce heart failure hospitalizations in this patient population. The re-labeling will allow it
The initial $500 million will be given in cash partially financed through treasury shares. An additional $100 million will be payable over two years subject to performance. Upon
Tipranavir is a non-peptidic protease inhibitor (PI) that requires boosting with low-dose ritonavir and must be used in combination with other antiretroviral agents. The committee’s positive recommendation is